IVIG for the treatment of toxic epidermal necrolysis.
Intravenous immunoglobulin (IVIG) has been proposed as a treatment for toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). A number of retrospective and prospective studies have been conducted, with varying levels of evidence for the efficacy of IVIG. Recent publications provide opposing conclusions. A multi-center, comparative, long-term analysis needs to be conducted to determine the role of IVIG in the management of patients with SJS/TEN.
Mittmann
N
N
Division of Clinical Pharmacology, University of Toronto, Ontario, Canada.
Chan
B C
BC
Knowles
S
S
Shear
N H
NH
D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*
D016756:Immunoglobulins, Intravenous